The completion of this study may positively influence Pfizer’s stock performance by demonstrating the effectiveness and safety of INLYTA® in real-world settings, potentially boosting investor ...

The purpose of investing in stocks is to make money, not lose it. So selling shares at a loss can be very upsetting. In this ...

Dow Jones Top Company Headlines at 11 AM ET: Meta Directors, Shareholders Settle Privacy Suit Before Board Members Testify at Trial | FDA ... Meta Directors, Shareholders Settle Privacy Suit Before ...

U.S. Bancorp notched a rise in earnings for the latest quarter as it benefited from a lower loan-loss provision and growth in fee income. The healthcare-products maker trimmed and narrowed its ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $133.42, a high estimate of $155.00, and a low estimate of $110.00. A negative shift in sentiment is evident ...

Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

President Trump announced potential tariffs on imported pharmaceuticals by month's end, followed by semiconductor levies.

This was the stock's third consecutive day of losses.

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...